TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$105 Million

Praxis Precision Medicines

Follow-on Offering

Bookrunner, May 2021

Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for people with prevalent, as well as rare, CNS disorders characterized by neuronal imbalance. The Company’s lead clinical program, PRAX-114, is an extrasynaptic-preferring GABAA receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression or PMD. Praxis’ second clinical program, PRAX-944, is a potential first-in-class selective small molecule inhibitor of T-type calcium channels, for the treatment of Essential Tremor (ET). The Company’s lead rare disease product candidate and third clinical program, PRAX-562, is a first-in-class selective persistent sodium current blocker for the treatment of a broad range of rare, devastating CNS disorders, such as severe pediatric epilepsy and adult cephalgia.